Takeda Pharmaceutical Co. Ltd. 4502
TSE · Japan · Health Technology
¥5,731.00-49.00 (-0.85%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Takeda Pharmaceutical (TSE:4502) has put its psoriasis pipeline in the spotlight after new Phase 3 LATITUDE data showed that investigational pill zasocitinib outperformed deucravacitinib on skin clearance measures in adults with moderate to severe plaque psoriasis. Taken together with Takeda Pharmaceutical’s oncology pipeline updates and recent leadership change in Spain, the psoriasis data arrives during a period of strong market performance, with the share price up 17.6% year to date and a...
Asian equities traded in the US as American depositary receipts were tracking modestly higher Wednes
Takeda (TAK) said Wednesday that its experimental pill zasocitinib showed superior results compared
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.